Skip to main content
. 2017 Sep 11;36:74. doi: 10.1186/s40880-017-0241-4

Fig. 1.

Fig. 1

Flowchart of patients with cancer-related pain who were randomized to receive either controlled-release oxycodone/naloxone (OXN-CR) or controlled-release oxycodone (OX-CR). aThe patient was found to have significant structural/functional abnormalities of the gastrointestinal tract which was deemed to be not appropriate for oral medicine administration